Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, General Review, Article, Review, Trends in Molecular Medicine called The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force, Author is Joisten, Niklas; Ruas, Jorge L.; Braidy, Nady; Guillemin, Gilles J.; Zimmer, Philipp, which mentions a compound: 492-27-3, SMILESS is O=C(C1=NC2=CC=CC=C2C(O)=C1)O, Molecular C10H7NO3, Quality Control of 4-Hydroxyquinoline-2-carboxylic Acid.
A review. A Review. The kynurenine (KYN) pathway (KP) of tryptophan (TRP) metabolism is dysregulated in inflammation-driven pathologies including oncol. and brain diseases [e.g., multiple sclerosis (MS), depression] and thus is a promising therapeutic target. Both pathol. and compensatory mechanisms underlie disease-associated KP activation. There is growing evidence for bioenergetic roles of certain KP metabolites such as kynurenic acid (KA), or quinolinic acid (QA) as an NAD+ precursor, which may explain its frequently observed ′pathol.′ overactivation. Disease- and tissue-specific aspects, neg. feedback on inflammatory signals, and the balance of downstream metabolites are likely to be decisive factors in the interpretation of an imbalanced KP. Therapeutic strategies should consider the compensatory actions and bioenergetic roles of KP metabolites to successfully design future theragnostic approaches aimed at attenuating disease progression.
There are many compounds similar to this compound(492-27-3)Quality Control of 4-Hydroxyquinoline-2-carboxylic Acid. if you want to know more, you can check out my other articles. I hope it will help you，maybe you’ll find some useful information.
Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”